


# Expected submission timelines<sup>(1)</sup>

Pipeline charts as communicated at Q3 2020  
Results Meeting dated October 29, 2020

NMEs

Additional Indications



As of September 30, 2020, barring unforeseen events

- (1) Excluding Phase 1 (without POC)
- (2) Projects within a specified year are not arranged by submission timing
- (3) Developed in collaboration with Regeneron
- (4) Also known as SAR439859
- (5) (Developed in collaboration with GSK and with funding from Biomedical Advanced Research and Development Authority (BARDA)
- (6) Developed in collaboration with Translate Bio
- (7) Acid Sphingomyelinase Deficiency
- (8) Developed in collaboration with Sobi
- (9) Autosomal Dominant Polycystic Kidney Disease
- (10) Proposed international nonproprietary name for SAR442168
- (11) Developed in collaboration with AstraZeneca
- (12) Parkinson's Disease with an associated GBA mutation
- (13) Immune Thrombocytopenia
- (14) Enzyme replacement therapy

MM: Multiple myeloma; CSCC: cutaneous squamous cell carcinoma; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; COPD: chronic obstructive pulmonary disease; Te: transplant eligible; Ti: transplant ineligible; ADPKD: Autosomal Dominant Polycystic Kidney Disease; ped: pediatric; NSCLC: non-small cell lung cancer; BCC: basal cell carcinoma; mBC: metastatic breast cancer